New York State Common Retirement Fund raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 260,296 shares of the company’s stock after purchasing an additional 4,895 shares during the period. New York State Common Retirement Fund owned 0.29% of Neurocrine Biosciences worth $15,951,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company increased its position in shares of Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares in the last quarter. World Asset Management Inc acquired a new position in shares of Neurocrine Biosciences during the third quarter worth $246,000. ARS Investment Partners LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter worth $207,000. Stephens Inc. AR acquired a new position in shares of Neurocrine Biosciences during the second quarter worth $207,000. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Neurocrine Biosciences during the third quarter worth $286,000.

Shares of Neurocrine Biosciences, Inc. (NBIX) opened at $70.49 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the previous year, the company posted ($0.43) earnings per share. equities research analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.

In other Neurocrine Biosciences news, insider Kyle Gano sold 24,818 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the sale, the insider now directly owns 84,596 shares of the company’s stock, valued at $6,010,545.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,877 shares of company stock worth $6,568,617. 4.80% of the stock is owned by corporate insiders.

A number of equities analysts have recently issued reports on NBIX shares. Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. ValuEngine raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Oppenheimer reissued a “buy” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Finally, Robert W. Baird reissued an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, September 21st. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average target price of $78.88.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Stake Boosted by New York State Common Retirement Fund” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/16/neurocrine-biosciences-inc-nbix-stake-boosted-by-new-york-state-common-retirement-fund.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related stocks with our FREE daily email newsletter.